Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment–Naive Patients Significantly Impact Treatment Outcomes
The Journal of Infectious Diseases2009Vol. 199(5), pp. 693–701
Citations Over TimeTop 1% of 2009 papers
Birgitte B. Simen, Jan Fredrik Simons, Katherine Huppler Hullsiek, Richard M. Novak, Rodger D. MacArthur, John D. Baxter, Chunli Huang, Christine K Lubeski, Gregory S. Turenchalk, Michael Braverman, Brian Desany, Jonathan M. Rothberg, Michael D. Miller, Michael J. Kozal
Abstract
Ultra-deep sequencing identified a significantly larger proportion of HIV-infected, treatment-naive persons as harboring drug-resistant viral variants. Among participants who initiated treatment with the NNRTI strategy, the risk of VF was significantly greater for participants who had low- and high-prevalence NNRTI-resistant variants.
Related Papers
- → Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter(1995)538 cited
- → Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV-1–Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy(2000)40 cited
- → Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV-1–Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy(2000)13 cited
- Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.(1997)
- → Emergence of Dual Resistance to Zidovudine and Lamivudine in Clinical HIV-1 Isolates from Patients Receiving Zidovudine/Lamivudine Combination Therapy(1998)11 cited